<table>
<thead>
<tr>
<th>Quality assessment</th>
<th>Study event rates (%)</th>
<th>Summary of Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>With no antiviral treatment</td>
<td>With amantadine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants (studies)</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
</tr>
<tr>
<td>Follow up to 30 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mortality</td>
<td>serious¹</td>
<td>no serious inconsistency</td>
</tr>
<tr>
<td></td>
<td>- not measured</td>
<td></td>
</tr>
<tr>
<td>Duration of hospitalisation (measured with: days; Better indicated by lower values)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>78 (1 study)</td>
<td>serious¹</td>
<td>no serious inconsistency</td>
</tr>
<tr>
<td>Duration of signs and symptoms (measured with: hours from onset of symptoms; Better indicated by lower values)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1508 (3 studies)</td>
<td>serious¹</td>
<td>serious²</td>
</tr>
<tr>
<td>Complications - Pneumonia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>139 (1 study)</td>
<td>serious¹</td>
<td>no serious inconsistency</td>
</tr>
<tr>
<td>Minor adverse events</td>
<td></td>
<td></td>
</tr>
<tr>
<td>832 (3 studies)</td>
<td>serious¹⁴</td>
<td>no serious inconsistency</td>
</tr>
</tbody>
</table>

¹ Studies not adjusted for potential confounding factors.
² Few events and participants.
³ Although we did not downgrade, publication bias cannot be excluded.
4 Studies did not have comparison groups.
5 High heterogeneity among studies.
6 The mean time to alleviation of symptoms for people who had amantadine was 64 hours (63 to 65 hours). There is no comparison group.